keyword
MENU ▼
Read by QxMD icon Read
search

Lacosamide

keyword
https://www.readbyqxmd.com/read/29758584/inhibition-of-sympathetic-sprouting-in-ccd-rats-by-lacosamide
#1
Yuying Wang, Fuquan Huo
BACKGROUND: Early hyperexcitability activity of injured nerve/neuron is critical for developing sympathetic nerve sprouting within dorsal root ganglia (DRG). Since lacosamide (LCM), an anticonvulsant, inhibits Na+ channel. The present study tried to test the potential effect of LCM on inhibiting sympathetic sprouting in vivo. METHODS: LCM (50 mg/kg) was daily injected intraperitoneally into rats subjected to chronic compression DRG (CCD), an animal model of neuropathic pain that exhibits sympathetic nerve sprouting, for the 1st 7 days after injury...
May 14, 2018: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29758445/intravenous-lacosamide-lcm-in-status-epilepticus-se-weight-adjusted-dose-and-efficacy
#2
Estevo Santamarina, Montserrat González-Cuevas, Manuel Toledo, Marta Jiménez, Juan Luis Becerra, Alex Quílez, Ana Suller, J A Mauri, Ángel Fernández, Ainhoa Marinas, Manuel Quintana, Xavier Salas Puig
BACKGROUND: Some studies suggest higher efficacy of lacosamide (LCM) in status epilepticus (SE) with higher loading doses; however, this weight-adjusted dose has not been evaluated. OBJECTIVE: The objective was to evaluate the relationship between loading weight-adjusted dose and efficacy of LCM in SE. METHODS: A group of patients with SE treated with LCM from Spanish hospitals was examined retrospectively. Demographic data, type of SE, etiology, response rate, last antiepileptic drug (AED) used, treatment line in which LCM was used, total loading dose, and weight-adjusted dose were collected...
May 11, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29733464/randomized-trial-of-lacosamide-vs-fosphenytoin-for-nonconvulsive-seizures
#3
Aatif M Husain, Jong W Lee, Bradley J Kolls, Lawrence J Hirsch, Jonathan J Halford, Puneet K Gupta, Yafa Minazad, Jennifer M Jones, Suzette M LaRoche, Susan T Herman, Christa B Swisher, Saurabh R Sinha, Adriana Palade, Keith E Dombrowski, William B Gallentine, Cecil D Hahn, Elizabeth E Gerard, Manjushri Bhapkar, Yuliya Lokhnygina, M Brandon Westover
OBJECTIVE: The optimal treatment of nonconvulsive seizures in critically ill patients is uncertain. We evaluated the comparative effectiveness of antiseizure drugs (ASD) lacosamide (LCM) and fosphenytoin (fPHT) in this population. METHODS: The Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) study was a non-inferiority, prospective, multicenter, randomized treatment trial of patients diagnosed with NCS by continuous electroencephalography (cEEG)...
May 7, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29730500/changes-in-antiepileptic-drug-prescribing-patterns-in-pregnant-women-with-epilepsy
#4
Kimford J Meador, Page B Pennell, Ryan C May, Elizabeth Gerard, Laura Kalayjian, Naymee Velez-Ruiz, Patricia Penovich, Jennifer Cavitt, Jaqueline French, Sean Hwang, Alison M Pack, Maria Sam, Eugene Moore, Dominic M Ippolito
OBJECTIVE: We analyzed current prescribing patterns for antiepileptic drugs (AEDs) in pregnant women with epilepsy (PWWE) at 20 USA tertiary epilepsy centers. METHODS: The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is an NIH-funded, prospective, observational, multicenter investigation of pregnancy outcomes for both mother and child, which enrolled women from December 2012 to January 2016. Inclusion criteria for PWWE included ages 14-45 years and up to 20 weeks gestational age...
May 3, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29719278/clinical-and-electrocorticographic-response-to-antiepileptic-drugs-in-patients-treated-with-responsive-stimulation
#5
Tara L Skarpaas, Thomas K Tcheng, Martha J Morrell
OBJECTIVE: The objective of this study was to explore whether chronic electrocorticographic (ECoG) data recorded by a responsive neurostimulation system could be used to assess clinical responses to antiepileptic drugs (AEDs). METHODS: Antiepileptic drugs initiated and maintained for ≥3 months by patients participating in clinical trials of the RNS® System were identified. Such "AED Starts" that produced an additional ≥50% reduction in patient-reported clinical seizure frequency were categorized as clinically beneficial, and the remaining as not beneficial...
April 29, 2018: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/29704679/evaluating-the-longer-term-cognitive-effects-of-adjunctive-perampanel-compared-to-lacosamide-in-a-naturalistic-outpatient-setting
#6
Carolin Meschede, Juri-Alexander Witt, Michael Rademacher, Randi D von Wrede, Christian E Elger, Christoph Helmstaedter
PURPOSE: This retrospective longitudinal study aims to compare the longer-term cognitive and behavioral side effects of adjunctive antiepileptic treatment with perampanel (PER) and lacosamide (LCM), two third generation antiepileptic drugs with suggested favorable cognitive profiles. The two drugs were monitored according to a previously established routine diagnostic protocol (Helmstaedter et al. E&B 2013;26:182-7) which facilitates the retrospective comparison of antiepileptic drug tolerability in a naturalistic outpatient setting...
April 22, 2018: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/29663335/long-term-efficacy-of-add-on-lacosamide-treatment-in-children-and-adolescents-with-refractory-epilepsies-a-single-center-observational-study
#7
Anna Rosati, Lucrezia Ilvento, Riccardo Rizzi, Viola Doccini, Maria Carmela Leo, Alessandra Pugi, Salvatore De Masi, Renzo Guerrini
OBJECTIVE: To assess long-term efficacy and tolerability of lacosamide (LCM) as adjunctive treatment through a retrospective study in children and adolescents with refractory epilepsies. METHODS: All patients consecutively treated with LCM as add-on for refractory focal and generalized epilepsy and followed at the Neuroscience Center of Excellence of the Meyer Children's Hospital of Florence between January 2011 and September 2015 were included in the study. Responder rate, relapse-free survival, and retention rate were calculated...
April 17, 2018: Epilepsia
https://www.readbyqxmd.com/read/29624640/why-we-prefer-levetiracetam-over-phenytoin-for-treatment-of-status-epilepticus
#8
G Zaccara, F S Giorgi, A Amantini, G Giannasi, R Campostrini, F Giovannelli, M Paganini, P Nazerian
Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam. Clinical studies have never shown a better efficacy of PHT over other antiepileptic drugs. In addition, iv PHT loading dose is a complex and time-consuming procedure which may expose patients to several risks, such as local cutaneous reactions (purple glove syndrome), severe hypotension and cardiac arrhythmias up to ventricular fibrillation and death, and increased risk of severe allergic reactions...
April 6, 2018: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29621596/a-novel-action-of-lacosamide-on-gaba-a-currents-sets-the-ground-for-a-synergic-interaction-with-levetiracetam-in-treatment-of-epilepsy
#9
Gabriele Ruffolo, Carlo Di Bonaventura, Pierangelo Cifelli, Cristina Roseti, Jinane Fattouch, Alessandra Morano, Cristina Limatola, Eleonora Aronica, Eleonora Palma, Anna Teresa Giallonardo
Epilepsy is one of the most common chronic neurological diseases, and its pharmacological treatment holds great importance for both physicians and national authorities, especially considering the high proportion of drug-resistant patients (about 30%). Lacosamide (LCM) is an effective and well-tolerated new-generation antiepileptic drug (AED), currently licensed as add-on therapy for partial-onset seizures. However, LCM mechanism of action is still a matter of debate, although its effect on the voltage sensitive sodium channels is by far the most recognized...
April 2, 2018: Neurobiology of Disease
https://www.readbyqxmd.com/read/29616753/isobolographic-additivity-among-lacosamide-lamotrigine-and-phenobarbital-in-a-mouse-tonic-clonic-seizure-model
#10
Maria W Kondrat-Wróbel, Jarogniew J Łuszczki
BACKGROUND: Epilepsy is a serious neurological disease affecting about 1% of people worldwide (65 million). Seizures are controllable with antiepileptic drugs (AEDs) in about 70% of epilepsy patients, however, there remains about 30% of patients inadequately medicated with these AEDs, who need a satisfactory control of their seizure attacks. For these patients, one of the treatment options is administration of 2 or 3 AEDs in combination. OBJECTIVES: To determine the anticonvulsant effects of a combination of 3 selected AEDs (i...
March 28, 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29616471/a-review-of-the-new-antiepileptic-drugs-for-focal-onset-seizures-in-pediatrics-role-of-extrapolation
#11
REVIEW
Alexis Arzimanoglou, O'Neill D'Cruz, Douglas Nordli, Shlomo Shinnar, Gregory L Holmes
Most antiepileptic drugs (AEDs) receive regulatory approval for children years after the drug is available in adults, encouraging off-label use of the drug in children and hindering attempts to obtain quality pediatric data in controlled trials. Extrapolating adult efficacy data to pediatrics can reduce the time between approval in adults and that in children. To extrapolate efficacy from adults to children, several assumptions must be supported, such as (1) a similar disease progression and response to interventions in adults and children, and (2) similar exposure response in adults and children...
April 3, 2018: Paediatric Drugs
https://www.readbyqxmd.com/read/29614316/lacosamide-protects-striatal-and-hippocampal-neurons-from-in-vitro-ischemia-without-altering-physiological-synaptic-plasticity
#12
Petra Mazzocchetti, Michela Tantucci, Guendalina Bastioli, Valeria Calabrese, Massimiliano Di Filippo, Alessandro Tozzi, Paolo Calabresi, Cinzia Costa
Lacosamide ([(R)-2-acetamido-N-benzyl-3-methoxypropanamide], LCM), is an antiepileptic that exerts anticonvulsant activity by selectively enhancing slow sodium channel inactivation. By inhibiting seizures and neuronal excitability it might therefore be a good candidate to stabilize neurons and protect them from energetic insults. Using electrophysiological analyses, we have investigated in mice the possible neuroprotective effect of LCM against in vitro ischemia obtained by oxygen and glucose deprivation (ODG), in striatal and hippocampal tissues, two brain structures particularly susceptible to ischemic injury and of pivotal importance for different form of learning and memory...
March 31, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29605232/chronic-treatment-with-the-new-anticonvulsant-drug-lacosamide-impairs-learning-and-memory-processes-in-rats-a-possible-role-of-bdnf-trkb-ligand-receptor-system
#13
Michaela Shishmanova-Doseva, Lyudmil Peychev, Yvetta Koeva, Dora Terzieva, Katerina Georgieva, Zhivko Peychev
Cognitive impairment is considered a frequent side effect in the drug treatment of epilepsy. The objective of the present study was to investigate the effects of lacosamide (LCM) on learning and memory processes in rats, on the serum level of brain-derived neurotrophic factor (BDNF) and BDNF/TrkB ligand receptor system expression in the hippocampal formation. Male Wistar rats underwent long-term treatment with three different doses of lacosamide - 3 mg/kg (LCM 3), 10 mg/kg (LCM 10) and 30 mg/kg (LCM 30)...
March 29, 2018: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/29588972/safety-and-tolerability-of-lacosamide-monotherapy-in-the-elderly-a-subgroup-analysis-from-lacosamide-trials-in-diabetic-neuropathic-pain
#14
Jacquelyn Bainbridge, Marc De Backer, Klaus Eckhardt, Frank Tennigkeit, Sabine Bongardt, David Sen, Konrad J Werhahn, Aziz Shaibani, Edward Faught
Objective: To assess the safety profile of lacosamide monotherapy in elderly (≥65 years) subjects with diabetic neuropathic pain (DNP). Methods: Of 1,863 DNP subjects in double-blind, randomized, placebo-controlled trials of lacosamide monotherapy (NCT00861445, NCT00235469, NCT00238524, NCT00135109, NCT00350103), 502 were elderly. Safety data from elderly subjects were compared with that of younger subjects (<65 years) within these DNP trials. It should be noted that lacosamide is approved for the treatment of focal (partial-onset) seizures; it is not approved/recommended for the treatment of DNP...
December 2017: Epilepsia Open
https://www.readbyqxmd.com/read/29588957/dress-syndrome-a-case-of-cross-reactivity-with-lacosamide
#15
Man Kei Fong, Bun Sheng
A 42-year-old patient with epilepsy was admitted to the hospital for fever and generalized skin rash. He has known allergy to phenytoin. Valproate was started in 2012, but failed to control his seizure despite gradual increase in dosage. Phenobarbitone was added 16 days before admission and was stopped on admission. He was treated with beta-lactam antibiotics. The rash subsided gradually after the cessation of phenobarbitone. Lacosamide was subsequently added for seizure control. Unfortunately, he developed drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome soon after introduction of lacosamide that required the use of systemic steroid for acute hepatitis...
June 2017: Epilepsia Open
https://www.readbyqxmd.com/read/29582404/newer-antiepileptic-drugs-for-status-epilepticus-in-adults-what-s-the-evidence
#16
REVIEW
Isabelle Beuchat, Jan Novy, Andrea O Rossetti
Status epilepticus (SE) is one of the most frequent neurological emergencies. Despite this, understanding of its pathophysiology and evidence regarding its management is limited. Rapid, effective, and well-tolerated treatment to achieve seizure cessation is advocated to prevent brain damage or potentially lethal outcomes. The last two decades have witnessed an exponential increase in the number of available antiepileptic drugs (AEDs). These compounds, especially lacosamide and levetiracetam, in view of their intravenous formulation, have been increasingly prescribed in SE...
March 26, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29561632/development-and-full-validation-of-an-innovative-hplc-diode-array-detection-technique-to-simultaneously-quantify-lacosamide-levetiracetam-and-zonisamide-in-human-plasma
#17
Joana Gonçalves, Gilberto Alves, Joana Bicker, Amílcar Falcão, Ana Fortuna
AIM: To implement pharmacokinetic drug monitoring and individualize the posology of new antiepileptic drugs, the first HPLC-diode array detection method was developed and validated to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma. MATERIALS & METHODS: Preceded by a reproducible liquid-liquid extraction, chromatographic separation was achieved by using a C18 column of 5 cm length and a mobile phase of water/acetonitrile. Full validation was performed according to international guidelines...
March 21, 2018: Bioanalysis
https://www.readbyqxmd.com/read/29547769/real-world-experience-with-lacosamide-monotherapy-a-single-center-1-year-follow-up-study
#18
Eimer Maloney, Ronan N McGinty, Daniel J Costello
PURPOSE: Reporting of 'real-world' data on efficacy and tolerability of antiepileptic medications helps to inform physicians on how newer medications perform in the clinical setting, outside of the strict regimens of clinical trials. We report our experience of prescribing lacosamide monotherapy to a diverse range of patients at our epilepsy centre. METHODS: We performed a single-centre, retrospective review of all patients who had been prescribed lacosamide monotherapy over the last 8 years...
March 8, 2018: Epilepsy Research
https://www.readbyqxmd.com/read/29542107/lacosamide-monotherapy-in-clinical-practice-a-retrospective-chart-review
#19
V Villanueva, B G Giráldez, M Toledo, G J De Haan, E Cumbo, A Gambardella, M De Backer, L Joeres, M Brunnert, P Dedeken, J Serratosa
OBJECTIVE: To assess effectiveness and tolerability of first-line and conversion to lacosamide monotherapy for focal seizures. MATERIALS AND METHODS: Retrospective, non-interventional chart review of lacosamide monotherapy patients aged ≥16 years in Europe. Outcomes included retention rate at observational point (OP) 3 (12 ± 3 months), seizure freedom rates at OP2 (6 ± 3 months) and OP3 and adverse drug reactions (ADRs). RESULTS: A total of 439 patients were included (98 first-line and 341 conversion to monotherapy; 128 aged ≥65 years [25 first-line and 103 conversion to monotherapy])...
March 14, 2018: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29537058/-lacosamide-associated-with-high-degree-block-in-a-patient-with-trigeminal-neuralgia
#20
M Marin-Gracia, D Cantero-Lozano, E Garces-Anton, A Lopez-Bravo, A Garrido-Fernandez, M P Navarro-Perez, S Santos-Lasaosa, M Garces-Redondo
INTRODUCTION: Lacosamide is an antiepileptic drug whose exact mechanism of action remains unknown. It acts by increasing the slow inactivation of the voltage-dependent sodium channels of the cell membranes. It is indicated in the treatment of focal seizures with or without secondary generalisation and is occasionally used as adjunct treatment in neuropathic pain. Although the most frequent side effects are mild (dizziness, diplopia, blurred vision, headache, tremor, etc.), others such as supraventricular tachyarrhythmias, changes in repolarisation, atrioventricular blocks and even cardiac arrest or sudden death have been reported...
March 16, 2018: Revista de Neurologia
keyword
keyword
6065
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"